Chengdu, China, July 14, 2021
Anticancer Bioscience Appoints Leader in Oncology Drug Development, Dr. Hong Liu, as US-based VP of Clinical Development
Chengdu, China, July 14, 2021 – Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, announced today the appointment of Dr. Hong Liu as VP of Clinical Development. A physician-scientist, he will be based in Chengdu and San Francisco.
ACB is commercializing inventions made in the J. Michael Bishop Institute of Cancer Research. In his earlier career, Dr. Liu previously worked with Nobel laureate Dr. J. Michael Bishop at the University of California, San Francisco alongside ACB’s Founder, President and CEO, Dun Yang. Dr. Liu will lead the development of ACB’s clinical strategy and will take responsibility for the preparation of data packages and IND filings with the US FDA.
ACB currently employs some 50 staff across its sites in China, India, UK and USA, and is expanding as it moves its discovery programs towards clinical development. The company aims to move at least one of its five programs into clinical development in the USA in 2022.
Welcoming Dr. Hong Liu to the team, ACB’s Founder, President and CEO, Dun Yang, PhD, said: “I am delighted that Dr. Liu is joining our team as we continue our development towards being a clinical-stage company. As a highly experienced R&D leader in the field of oncology drug development, Dr. Liu will be a great addition to our world-class team as we progress our pipeline of assets, focused on synthetic lethality approaches. His appointment supports our ongoing mission to grow ACB into a leading international precision oncology company.”
Dr. Liu commented on his appointment: “I welcome the opportunity of taking cancer drug candidates from IND-filing, and into the clinic. I am excited to be joining the ambitious team at ACB that is pioneering synthetic lethal approaches to cancer treatment and look forward to using my experience in oncology drug development to advance ACB’s unique pipeline of MYC-synthetic lethal drugs.”
Dr. Liu joins ACB from California-based Eureka Therapeutics where he served as VP of R&D and successfully took multiple drug candidates from discovery to IND filing. In his role, he also supervised the clinical research and clinical trial operation in China for the Company. Dr. Liu undertook his Ph.D. studies at UC Berkeley in the laboratory of Dr. Mina Bissell, a renowned cancer researcher and member of the US National Academy of Sciences. Prior to moving to the Dr. J. Michael Bishop lab at the University of California, Dr. Liu was a physician at the 1st Affiliated Hospital of Xi’an Jiaotong University.
Having raised CNY131M (approximately USD21M) in seed finance to fund its discovery research, ACB is currently pursuing a Series A financing to progress at least one of its MYC-SL compounds into clinical trials.
-ENDS-
For further information please contact
At the company
Anticancer Bioscience:
bd@anticancerbio.com
Media Relations
Scius Communications
Sue Charles
+44 (0) 7968 726585
sue@sciuscommunications.com
About Anticancer Bioscience
Anticancer Bioscience (ACB) is an international private company, commercializing discoveries emerging from China’s world-leading cancer research at the J. Michael Bishop Institute of Cancer Research. With pioneers in synthetic lethal approaches to precision oncology and experts in MYC biology and cell division, ACB was founded in 2016 in Chengdu, China. ACB is based on over 20 years of collaborative research between the founder Dr. Dun Yang and his Nobel laureate mentor Dr. J. Michael Bishop. It has raised CNY131M (around USD21M) and has around 50 employees in Chengdu, China, Hyderabad, India, Sydney, Australia, St Andrews, UK, and San Francisco, USA.
